Docetaxel

• Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting
  2023-506288-33-00 Phase I/II 8 countries Merck Sharp & Dohme LLC
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 Phase III 12 countries Merus N.V.
• Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo… Recruiting
  2024-516777-77-00 Phase II 1 country Vall D Hebron Institute Of Oncology
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting
  2023-509340-10-00 Phase III 11 countries OSE Immunotherapeutics
• DAROTAXEL Recruiting
  2024-516939-28-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Ezabenlimab (BI 754091) and DCFm (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal… Recruiting
  2024-514083-31-00 Phase II 1 country Centre Hospitalier Regional Universitaire
• Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting
  2023-505298-34-00 Phase II 1 country Unicancer
• Ebastine in combination with docetaxel or as a treatment for metastatic castration-resistant prostate cancer Recruiting
  2024-518035-11-01 Phase II 1 country Rigshospitalet
• European Larynx Organ Preservation Study (ELOS) Recruiting
  2022-502751-61-00 Phase II 1 country University of Leipzig
• Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting
  2022-502254-13-00 Phase III 1 country UZ Leuven
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: … Recruiting
  2024-515981-14-00 Phase III 1 country Azienda Ospedaliera Universitaria Integrata Verona
• A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors Recruiting
  2023-503651-10-00 Phase I (FiH) 3 countries Bristol-Myers Squibb Services Unlimited Company
• HIPEC/FLOT9 - PREVENT Recruiting
  2024-517300-10-01 Phase III 1 country Krankenhaus Nordwest GmbH
• RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line… Recruiting
  2024-518623-30-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Pre-operative capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric cancer (PANDA) Recruiting
  2024-519075-26-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting
  2023-506987-15-00 Phase I/II 11 countries Merck Sharp & Dohme LLC
• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 Phase II/III 10 countries The University Of Birmingham
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended
  2024-512998-27-00 Phase III 15 countries Genmab A/S
• A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended
  2023-508276-11-00 Phase III 5 countries AstraZeneca AB
• A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab… Ended
  2024-511650-50-00 Phase III 11 countries Pfizer Inc.
• A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended
  2024-516530-36-00 Phase III 1 country Cancer Trials Ireland
• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended
  2023-505423-31-00 Phase III 7 countries Merck Sharp & Dohme LLC

Showing 49–72 of 127 trials